Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 19;2(1):9-10.
doi: 10.1002/bco2.49. eCollection 2021 Jan.

Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure

Jennifer Uribe  1 , Santiago Uribe-Lewis  1 , Sara Khaksar  1 , Carla Perna  1 , Christos Mikropoulos  1 , Sophie Otter  1 , Robert Laing  1 , Stephen Langley  1
Affiliations
Editorial

Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure

Jennifer Uribe et al. BJUI Compass. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

JU and SUL report personal fees from BXTAccelyon Limited and Theragenics Corporation, outside the submitted work. SL and RL report personal fees, nonfinancial support, and other from BXTAccelyon Limited, outside the submitted work. SK, CP, CM, and SO have nothing to disclose. All authors have read and approved the final article.

Figures

FIGURE 1
FIGURE 1
Kaplan‐Meier relapse‐free survival analysis of patients who received LDR‐PB (alone or as combination with ADT and/or EBRT) stratified by their PSA value (ng/mL) 48 months post‐implant
See this image and copyright information in PMC

References

    1. Available from: https://www.auanet.org/Documents/education/clinical‐guidance/Clinically‐...
    1. Crook JM, Tang C, Thames H, Blanchard P, Sanders J, Ciezki J, et al. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol. 2020;27(149):64–9. - PMC - PubMed
    1. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE‐RT trial): an analysis of survival endpoints for a randomized trial comparing a low‐dose‐rate brachytherapy boost to a dose‐escalated external beam boost for high‐ and intermediate‐risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;1(98):275–85. - PubMed
    1. Morris WJ, Pickles T, Keyes M. Using a surgical prostate‐specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate‐ and high‐risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE‐RT randomized control trial. Brachytherapy. 2018;17:837–44. - PubMed
    1. Therneau T. A package for survival analysis in R. 2020. Available from https://CRAN.R‐project.org/package=survival

Publication types

LinkOut - more resources